Copyright Reports & Markets. All rights reserved.

Global Adoptive Cellular Immunotherapy Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Adoptive Cellular Immunotherapy Market Overview

    • 1.1 Product Overview and Scope of Adoptive Cellular Immunotherapy
    • 1.2 Classification of Adoptive Cellular Immunotherapy by Types
      • 1.2.1 Global Adoptive Cellular Immunotherapy Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Adoptive Cellular Immunotherapy Revenue Market Share by Types in 2018
      • 1.2.3 TIL
      • 1.2.4 LAK
      • 1.2.5 CAR-T
      • 1.2.6 TCR-T
      • 1.2.7 CIK
      • 1.2.8 NK
      • 1.2.9 DC
      • 1.2.10 Other
    • 1.3 Global Adoptive Cellular Immunotherapy Market by Application
      • 1.3.1 Global Adoptive Cellular Immunotherapy Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Hospital
      • 1.3.3 Cancer Hospital
      • 1.3.4 Centers for Disease Control and Prevention
      • 1.3.5 Rehabilitation Center
      • 1.3.6 Other
    • 1.4 Global Adoptive Cellular Immunotherapy Market by Regions
      • 1.4.1 Global Adoptive Cellular Immunotherapy Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Adoptive Cellular Immunotherapy Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Adoptive Cellular Immunotherapy Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Adoptive Cellular Immunotherapy Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Adoptive Cellular Immunotherapy Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Adoptive Cellular Immunotherapy Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Adoptive Cellular Immunotherapy (2014-2024)

    2 Manufacturers Profiles

    • 2.1 Amgen Inc
      • 2.1.1 Business Overview
      • 2.1.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Amgen Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Autolus Therapeutics Plc
      • 2.2.1 Business Overview
      • 2.2.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Autolus Therapeutics Plc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Beijing Immunochina Medical Science & Technology Co Ltd
      • 2.3.1 Business Overview
      • 2.3.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Beijing Immunochina Medical Science & Technology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Bellicum Pharmaceuticals Inc
      • 2.4.1 Business Overview
      • 2.4.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Bellicum Pharmaceuticals Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Bristol-Myers Squibb Co
      • 2.5.1 Business Overview
      • 2.5.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Bristol-Myers Squibb Co Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 bluebird bio Inc
      • 2.6.1 Business Overview
      • 2.6.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 bluebird bio Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 CARsgen Therapeutics Ltd
      • 2.7.1 Business Overview
      • 2.7.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 CARsgen Therapeutics Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Celgene Corp
      • 2.8.1 Business Overview
      • 2.8.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Celgene Corp Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Cell Medica Ltd
      • 2.9.1 Business Overview
      • 2.9.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Cell Medica Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Cellular Biomedicine Group Inc
      • 2.10.1 Business Overview
      • 2.10.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Cellular Biomedicine Group Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Celularity Inc
      • 2.11.1 Business Overview
      • 2.11.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Celularity Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.12 Celyad SA
      • 2.12.1 Business Overview
      • 2.12.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.12.2.1 Product A
        • 2.12.2.2 Product B
      • 2.12.3 Celyad SA Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.13 Daiichi Sankyo Co Ltd
      • 2.13.1 Business Overview
      • 2.13.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.13.2.1 Product A
        • 2.13.2.2 Product B
      • 2.13.3 Daiichi Sankyo Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.14 Fosun Pharmaceutical AG
      • 2.14.1 Business Overview
      • 2.14.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.14.2.1 Product A
        • 2.14.2.2 Product B
      • 2.14.3 Fosun Pharmaceutical AG Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.15 Gilead Sciences Inc
      • 2.15.1 Business Overview
      • 2.15.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.15.2.1 Product A
        • 2.15.2.2 Product B
      • 2.15.3 Gilead Sciences Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.16 Guangzhou Anjie Biomedical Technology Co Ltd
      • 2.16.1 Business Overview
      • 2.16.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.16.2.1 Product A
        • 2.16.2.2 Product B
      • 2.16.3 Guangzhou Anjie Biomedical Technology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.17 Hangzhou Converd Co Ltd
      • 2.17.1 Business Overview
      • 2.17.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.17.2.1 Product A
        • 2.17.2.2 Product B
      • 2.17.3 Hangzhou Converd Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.18 Hebei Senlang Biotechnology Inc Ltd
      • 2.18.1 Business Overview
      • 2.18.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.18.2.1 Product A
        • 2.18.2.2 Product B
      • 2.18.3 Hebei Senlang Biotechnology Inc Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.19 HRAIN Biotechnology Co Ltd
      • 2.19.1 Business Overview
      • 2.19.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.19.2.1 Product A
        • 2.19.2.2 Product B
      • 2.19.3 HRAIN Biotechnology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.20 Juno Therapeutics Inc
      • 2.20.1 Business Overview
      • 2.20.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.20.2.1 Product A
        • 2.20.2.2 Product B
      • 2.20.3 Juno Therapeutics Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.21 Kite Pharma Inc
      • 2.21.1 Business Overview
      • 2.2.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.21.2.1 Product A
        • 2.21.2.2 Product B
      • 2.21.3 Kite Pharma Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.22 Nanjing Legend Biotech Co Ltd
      • 2.22.1 Business Overview
      • 2.22.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.22.2.1 Product A
        • 2.22.2.2 Product B
      • 2.22.3 Nanjing Legend Biotech Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.23 NantKwest Inc
      • 2.23.1 Business Overview
      • 2.23.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.23.2.1 Product A
        • 2.23.2.2 Product B
      • 2.23.3 NantKwest Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.24 Nkarta Inc
      • 2.24.1 Business Overview
      • 2.24.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.24.2.1 Product A
        • 2.24.2.2 Product B
      • 2.24.3 Nkarta Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.25 Novartis AG
      • 2.25.1 Business Overview
      • 2.25.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.25.2.1 Product A
        • 2.25.2.2 Product B
      • 2.25.3 Novartis AG Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.26 Ono Pharmaceutical Co Ltd
      • 2.26.1 Business Overview
      • 2.26.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.26.2.1 Product A
        • 2.26.2.2 Product B
      • 2.26.3 Ono Pharmaceutical Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
      • 2.27.1 Business Overview
      • 2.27.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.27.2.1 Product A
        • 2.27.2.2 Product B
      • 2.27.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.28 Sorrento Therapeutics Inc
      • 2.28.1 Business Overview
      • 2.28.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.28.2.1 Product A
        • 2.28.2.2 Product B
      • 2.28.3 Sorrento Therapeutics Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.29 Takara Bio Inc
      • 2.29.1 Business Overview
      • 2.29.2 Adoptive Cellular Immunotherapy Type and Applications
        • 2.29.2.1 Product A
        • 2.29.2.2 Product B
      • 2.29.3 Takara Bio Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Adoptive Cellular Immunotherapy Market Competition, by Players

    • 3.1 Global Adoptive Cellular Immunotherapy Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Adoptive Cellular Immunotherapy Players Market Share
      • 3.2.2 Top 10 Adoptive Cellular Immunotherapy Players Market Share
    • 3.3 Market Competition Trend

    4 Global Adoptive Cellular Immunotherapy Market Size by Regions

    • 4.1 Global Adoptive Cellular Immunotherapy Revenue and Market Share by Regions
    • 4.2 North America Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 4.5 South America Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

    5 North America Adoptive Cellular Immunotherapy Revenue by Countries

    • 5.1 North America Adoptive Cellular Immunotherapy Revenue by Countries (2014-2019)
    • 5.2 USA Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

    6 Europe Adoptive Cellular Immunotherapy Revenue by Countries

    • 6.1 Europe Adoptive Cellular Immunotherapy Revenue by Countries (2014-2019)
    • 6.2 Germany Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 6.3 UK Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 6.4 France Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Countries

    • 7.1 Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Countries (2014-2019)
    • 7.2 China Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 7.5 India Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

    8 South America Adoptive Cellular Immunotherapy Revenue by Countries

    • 8.1 South America Adoptive Cellular Immunotherapy Revenue by Countries (2014-2019)
    • 8.2 Brazil Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Adoptive Cellular Immunotherapy by Countries

    • 9.1 Middle East and Africa Adoptive Cellular Immunotherapy Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

    10 Global Adoptive Cellular Immunotherapy Market Segment by Type

    • 10.1 Global Adoptive Cellular Immunotherapy Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Adoptive Cellular Immunotherapy Market Forecast by Type (2019-2024)
    • 10.3 TIL Revenue Growth Rate (2014-2024)
    • 10.4 LAK Revenue Growth Rate (2014-2024)
    • 10.5 CAR-T Revenue Growth Rate (2014-2024)
    • 10.6 TCR-T Revenue Growth Rate (2014-2024)
    • 10.7 CIK Revenue Growth Rate (2014-2024)
    • 10.8 NK Revenue Growth Rate (2014-2024)
    • 10.9 DC Revenue Growth Rate (2014-2024)
    • 10.10 Other Revenue Growth Rate (2014-2024)

    11 Global Adoptive Cellular Immunotherapy Market Segment by Application

    • 11.1 Global Adoptive Cellular Immunotherapy Revenue Market Share by Application (2014-2019)
    • 11.2 Adoptive Cellular Immunotherapy Market Forecast by Application (2019-2024)
    • 11.3 Hospital Revenue Growth (2014-2019)
    • 11.4 Cancer Hospital Revenue Growth (2014-2019)
    • 11.5 Centers for Disease Control and Prevention Revenue Growth (2014-2019)
    • 11.6 Rehabilitation Center Revenue Growth (2014-2019)
    • 11.7 Other Revenue Growth (2014-2019)

    12 Global Adoptive Cellular Immunotherapy Market Size Forecast (2019-2024)

    • 12.1 Global Adoptive Cellular Immunotherapy Market Size Forecast (2019-2024)
    • 12.2 Global Adoptive Cellular Immunotherapy Market Forecast by Regions (2019-2024)
    • 12.3 North America Adoptive Cellular Immunotherapy Revenue Market Forecast (2019-2024)
    • 12.4 Europe Adoptive Cellular Immunotherapy Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Adoptive Cellular Immunotherapy Revenue Market Forecast (2019-2024)
    • 12.6 South America Adoptive Cellular Immunotherapy Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Adoptive Cellular Immunotherapy Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Adoptive cellular immunity is the transfer of lymphocytes from the donor to the recipient to enhance its cellular immunity.

      Scope of the Report:
      The global Adoptive Cellular Immunotherapy market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Adoptive Cellular Immunotherapy.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Adoptive Cellular Immunotherapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Adoptive Cellular Immunotherapy market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Amgen Inc
      Autolus Therapeutics Plc
      Beijing Immunochina Medical Science & Technology Co Ltd
      Bellicum Pharmaceuticals Inc
      Bristol-Myers Squibb Co
      bluebird bio Inc
      CARsgen Therapeutics Ltd
      Celgene Corp
      Cell Medica Ltd
      Cellular Biomedicine Group Inc
      Celularity Inc
      Celyad SA
      Daiichi Sankyo Co Ltd
      Fosun Pharmaceutical AG
      Gilead Sciences Inc
      Guangzhou Anjie Biomedical Technology Co Ltd
      Hangzhou Converd Co Ltd
      Hebei Senlang Biotechnology Inc Ltd
      HRAIN Biotechnology Co Ltd
      Juno Therapeutics Inc
      Kite Pharma Inc
      Nanjing Legend Biotech Co Ltd
      NantKwest Inc
      Nkarta Inc
      Novartis AG
      Ono Pharmaceutical Co Ltd
      Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
      Sorrento Therapeutics Inc
      Takara Bio Inc

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      TIL
      LAK
      CAR-T
      TCR-T
      CIK
      NK
      DC
      Other

      Market Segment by Applications, can be divided into
      Hospital
      Cancer Hospital
      Centers for Disease Control and Prevention
      Rehabilitation Center
      Other

      Buy now